Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-3 - 6

University of Colorado Denver (CU Denver)

Status and phase: Withdrawn; Phase 2

Conditions: Heroin Dependence; Opioid-Related Disorders

Treatments: Drug: Placebo Drug; Drug: Test Drug

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00000331

R01DA011160 (U.S. NIH Grant/Contract)

NIDA-11160-6

R01-11160-6

Details and patient eligibility

About

The purpose of this study is to assess the abuse liability and examine the reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in healthy, non-drug dependent volunteers.

Full description

not available at this time

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Individuals must be healthy, non-drug dependent volunteers, be at least 18 years of age, and have no prior history of drug or alcohol abuse or dependence. Subjects must have had some minimal experience with opioids (e.g. at least two prior exposures)

Exclusion criteria

Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g., liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Trial design

0 participants in 2 patient groups, including a placebo group

Test Drug

Experimental group

Description:

Test drug to prevent heroine withdrawal

Treatment:

Drug: Test Drug

Placebo Pill

Placebo Comparator group

Description:

Placebo drug

Treatment:

Drug: Placebo Drug